This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kersemaekers, A.-M. F. Articles by Looijenga, L. H.J. Search for Related Content PubMed PubMed Citation Articles by Kersemaekers, A.-M. F. Articles by Looijenga, L. H.J.

Role of P53 and MDM2 in Treatment Response of Human Germ Cell Tumors

From the Department of Pathology/Laboratory for Experimental Patho-Oncology, University Hospital Rotterdam/Daniel, Josephine Nefkens Institute, Erasmus University Rotterdam, Rotterdam, the Netherlands, and Department of Hematology/Oncology, University of Tübingen, Tübingen, Germany.

Address reprint requests to Department of Pathology/Laboratory for Experimental Patho-Oncology, University Hospital Rotterdam/Daniel, Josephine Nefkens Institute, Erasmus University Rotterdam, Bldg Be 431, Rm 430b, PO Box 1738, 3000 DR Rotterdam, the Netherlands; email: Looijenga{at}leph.azr.nl

PURPOSE: Testicular germ cell tumors (TGCTs) of adolescents and adults are very sensitive to systemic treatment. The exquisite chemosensitivity of these cancers has been attributed to a high level of wild-type P53.

MATERIALS AND METHODS: To clarify the role of P53 in treatment sensitivity and resistance of TGCTs, we performed immunohistochemistry and Western blotting analysis on a series of 39 fresh-frozen primary TGCTs before therapy (unselected series). In a series of formalin-fixed paraffin-embedded TGCTs of patients with fully documented clinical course, including treatment-sensitive (n = 17) and -resistant (n = 18) tumors, P53 status was assessed by immunohistochemistry and mutation analysis. In addition, the involvement of MDM2, a P53 antagonist, was investigated by immunohistochemistry, reverse transcriptase polymerase chain reaction, and in situ hybridization.

RESULTS: Immunohistochemistry demonstrated absence of staining for P53 in 36%, 41%, and 17% of the unselected, responding, and nonresponding TGCTs, respectively. Of the positive TGCTs, most tumors, ie, 49%, 41%, and 33%, showed 1% to 10% positive nuclei. This overall low level of P53 was confirmed by Western blotting. Mutation analysis revealed only one silent P53 mutation in one of the responding patients. All embryonal carcinomas were homogeneously positive for MDM2, encoded by the full length mRNA, while a heterogeneous pattern was found for the other histologic components. Amplification of MDM2 was detected in one out of 12 embryonal carcinomas.

CONCLUSION: Although our results are in line with previous findings of the presence of wild-type P53 in TGCTs, they show that a high level of P53 does not relate directly to treatment sensitivity of these tumors, and inactivation of P53 is not a common event in the development of cisplatin resistance.

The first two authors contributed equally to the work.

This article has been cited by other articles:

				M. Mazumdar, J. Bacik, S. K. Tickoo, D. Dobrzynski, A. Donadio, D. Bajorin, R. Motzer, V. Reuter, and G. J. Bosl Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor J. Clin. Oncol., July 15, 2003; 21(14): 2679 - 2688. [Abstract] [Full Text] [PDF]

				L. H. J. Looijenga, H. Stoop, H. P. J. C. de Leeuw, C. A. de Gouveia Brazao, A. J. M. Gillis, K. E. P. van Roozendaal, E. J. J. van Zoelen, R. F. A. Weber, K. P. Wolffenbuttel, H. van Dekken, et al. POU5F1 (OCT3/4) Identifies Cells with Pluripotent Potential in Human Germ Cell Tumors Cancer Res., May 1, 2003; 63(9): 2244 - 2250. [Abstract] [Full Text] [PDF]

				F. Mayer, H. Stoop, G. L. Scheffer, R. Scheper, J. W. Oosterhuis, L. H. J. Looijenga, and C. Bokemeyer Molecular Determinants of Treatment Response in Human Germ Cell Tumors Clin. Cancer Res., February 1, 2003; 9(2): 767 - 773. [Abstract] [Full Text] [PDF]

				R.T.D. Oliver, J. Shamash, D.M. Berney, F. Mayer, A.-M. Kersemaekers, J. W. Oosterhuis, C. Bokemeyer, and L. H.J. Looijenga p53 and MDM2 in Germ Cell Cancer Treatment Response J. Clin. Oncol., September 15, 2002; 20(18): 3928 - 3929. [Full Text] [PDF]

				F. Mayer, A. J. M. Gillis, W. Dinjens, J. W. Oosterhuis, C. Bokemeyer, and L. H. J. Looijenga Microsatellite Instability of Germ Cell Tumors Is Associated with Resistance to Systemic Treatment Cancer Res., May 1, 2002; 62(10): 2758 - 2760. [Abstract] [Full Text] [PDF]